Pipeline
Cornerstone’s lead compound, CPI-613® (devimistat), is being evaluated in clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with solid tumors or blood cancers.
![Clinical Studies Graph](https://cornerstonepha.wpengine.com/wp-content/uploads/Rafael-Pharma_Pipeline_March-2022_v1.0.png)
Cornerstone’s lead compound, CPI-613® (devimistat), is being evaluated in clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with solid tumors or blood cancers.